ArticleOncology letters2025
MicroRNA‑96 promotes the proliferation and migration of breast cancer cells by inhibiting Smad7 expression.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the effects of microRNA (miR)-96 on the proliferation and migration of breast cancer cells, and indicated that miR-96 may have a promoting role in breast cancer by inhibiting Smad7. Reverse transcription-quantitative (RT-q)PCR was used to detect the expression levels of miR-96 and Smad7 in breast cancer tissues and adjacent tissues. Western blotting and immunohistochemistry were conducted to determine the expression levels of SMAD7 in breast cancer and adjacent tissues. A dual luciferase assay was performed to verify the targeted binding between miR-96 and Smad7. Furthermore, the different expression patterns of miR-96 and Smad7 were compared in various breast cancer cell lines using RT-qPCR and western blotting. Among these cell lines, MDA-MB-231, which exhibited the highest expression of miR-96, was chosen for subsequent functional verification. The expression levels of miR-96 were significantly higher in breast cancer tissues compared with those in adjacent tissues. By contrast, the expression levels of Smad7 were significantly lower in breast cancer tissues compared with those in adjacent tissues. The dual luciferase assay revealed a targeted binding effect between miR-96 and Smad7. Notably, transfection with miR-96-5p mimics and short hairpin RNA-Smad7 markedly promoted the proliferation, adhesion, invasion and migration of breast cancer cells. Conversely, transfection with a miR-96-5p inhibitor and Smad7 overexpression plasmid exhibited the opposite trend. In conclusion, the expression levels of miR-96 were significantly elevated in breast cancer tissues compared with those in adjacent tissues. Overexpression of miR-96 was shown to promote the migration of breast cancer cells by downregulating the expression of Smad7. These findings indicated that miR-96 may serve as a prognostic marker for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.